PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1895, no persons are required to respond to a callection of information unless it contains a valid OMB under

Substitute for form 1449/PTO				Complete if known		
(EV61:	5581113U	S)		Application Number	09/942,463	
INFORMATION DISCLOSURE			OCUDE	Filing Date	August 29, 2001	
				First Named Inventor	Nikos Panayotatos	
STAT	(use as many sheets as necessary)			Art Unit	2165	
(use				Examiner Name	Carlos A. Azpuru	
Sheet	1	of	2	Attorney Docket Number	NP/1 CIP DIV 1	

	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	t₫
	No.	camy cam' - Number² - Kas cass³	MM#DD-YYYY	Applicant of Cited Documents	Passages or Relevant Figures Appear	
7A		0 501 309 A1	02/09/1992	Asakawa et al.		
		NON PA	ATENT LITERA	TURE DOCUMENTS		
		1				
Examiner initials*	Cite No.1	Include name of the author (ii	n CAPITAL LETTERS), posium, catalog, etc.), c	TURE DOCUMENTS title of the article (when appropriate), late, page(s), volume-issue number(s) where published		T [©]
		Include name of the author (ii magazine, journal, serial, sym	n CAPITAL LETTERS), posium, catalog, etc.), c country v	title of the article (when appropriate), late, page(s), volume-issue number(s)	, publisher, city and-or	T [©]

Examiner Cite initials* No.1		magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published				
1	/	Allen, T.M., "Long-circulating (sterically stabilized) liposomes for targeted drug delivery," <i>Trends Pharm. Sci.</i> , 15(7):215-220 (1994).				
		Allen et al., "Antibody-mediated targeting of long-circulating (stealth) liposomes," J. Liposome Res., 4(1):1-25 (1994).				
		Breeze et al., "Delivery of cytotoxic drugs to cancer patients using low density lipoprotein," J. Controlled Release, 28:321-322 (1994).				
		Citro et al., "Inhibition of leukemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligonucleotides into HL-60 cells," Br. J. Cancer, 69:463-467 (1994).				
		Kim et al., "Development of specific organ-targeting drug delivery system I: physico-pharmaceutical characteristics of thermally denatured albumin microspheres containing cytarabine," <i>Arch. Pharm. Res.</i> , 8(3):159-168 (1985).				
		Kramer P. A., "Albumin microspheres as vehicles for achieving specificity in drug delivery," J. Pharm. Sci., 63(10):1646-1647 (1974).				
		Morimoto et al., "Drug-carrier property of albumin microspheres in chemotherapy. V. Antitumor effect of microsphere-entrapped adriamycin on liver metastasis of AH 7974 cells in rats," <i>Chem. Pharm. Bull.</i> , 29(5):1433-1438 (1981).				
		Newton D. W., "Biotechnology frontier: targeted drug delivery," U.S. Pharmacist, 16(4):38-39 (1991).				

Examiner Signature	end	-Gn	Date Considered	4/13/25
-----------------------	-----	-----	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not claston is in conformance with MPEP 609. Draw line through otation if not in conformance and not considered, include copy of this form with next communication to applicant. (I Applicant's unique claston designation number (optional). 2 See Kinds Codes of USPTO Patent Documents of www.uspto.gov.or MPEP 801.04. 3 Enter Office that issued the document, bytho two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place or check mark-there if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2 3 2 0 2 0 5 E

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE

Under the Page Nork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	TO ENEMANT 44	19/PT	0	Complete if known		
				Application Number	09/942,463	
INFO	DRMATION	DISC	CLOSURE	Filing Date	August 29, 2001	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Nikos Panayotatos	
• • • • • • • • • • • • • • • • • • • •			. 2.07	Art Unit	2165	
(use as many sheets as necessary)				Examiner Name	Carlos A. Azpuru	
Sheet	2	of	2	Attorney Docket Number	NP/1 CIP DIV 1	

	NON PATENT LITERATURE DOCUMENTS	
A	Sugibayashi et al., "Drug-carrier property of albumin microspheres in chemotherapy. II. Preparation and tissue distribution in mice of microsphere-entrapped 5-fluorouracil," <i>Chem. Pharm. Bull.</i> , 27(1):204-209 (1979).	
OB	Wagner et al., "Delivery of drugs, proteins and genes into cells using transferring as a ligand for receptor-mediated endocytosis," Adv. Drug Del. Rev., 14:113-135 (1994).	

Examiner Signature Date Considered 4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through dilation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's indigue citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www uspin gover MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese potent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place or check many here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.